Protocol for Kinase activity and phosphorylation assays

Reagents and chemicals

• Use pathway stimulus or inhibitor, vehicle control, formaldehyde or paraformaldehyde for rapid fixation, methanol for phospho-epitope permeabilization, staining buffer, wash buffer, and viability dye when compatible with fixation because phosphorylation can change rapidly during handling^[1][2][5].

Antibodies, probes, dyes, or kits

• Use fluorophore-conjugated phospho-specific antibodies for targets such as pERK, pSTAT, pAKT, pS6, or pp38; use cell-surface antibodies to define cell subsets; use single-color compensation reagents and fluorescence-minus-one controls for gating; use C11-BODIPY only when combining pathway analysis with ferroptosis-associated lipid peroxidation^{[1][2][3][4][6]}.

Cells, tissues, isolated organs, organoids, or animals

• Use single-cell suspensions from cancer cell lines, primary neurons, mouse tumor tissue, inflammatory macrophages, blood or spleen leukocytes, or dissociated organoids; exclude clumped or poorly dissociated samples because flow cytometry requires single cells^[2][3][4][7].

Buffers and solutions

• Use fixation buffer to arrest signaling, methanol or validated detergent/alcohol permeabilization conditions to expose phospho-epitopes, antibody staining buffer to reduce nonspecific binding, and wash buffer to remove unbound antibody^[1][2][5].

Equipment and instruments

• Use biosafety cabinet, CO₂ incubator, centrifuge, cell strainer when preparing tissues, ice bucket, calibrated pipettes, flow cytometer with appropriate lasers and detectors, and analysis software for compensation, gating, and median fluorescence intensity analysis^[3][4].

Controls

• Include unstimulated control, stimulated positive control, inhibitor-treated control, vehicle control, unstained cells, single-stained compensation controls, FMO controls, isotype controls only when specifically informative, viability control, and matched total-cell subset markers^[1][2][3][4].

Select an experimental protocol

• Define the kinase, phosphorylation site, sample type, and primary readout before starting; use direct kinase activity assays when enzyme catalytic activity is the question, and use phospho-Western blot, immunofluorescence, or phospho-flow when the question is pathway phosphorylation inside cells or tissues^[1][2][3][4].
• Prepare cells, organoids, macrophages, neurons, or tumor tissues under the experimental treatment conditions, then collect samples rapidly with phosphatase inhibitors because phospho-epitopes are labile and may be altered during tissue handling or fixation^[3][4][5].
• For drug screening, first optimize enzyme amount, ATP concentration, substrate concentration, reaction time, detection linearity, signal window, and DMSO tolerance rather than assuming a universal kinase-assay condition^[2][13].

Experimental protocol case-by-case

• Step 1: For phospho-Western blot, lyse samples in phosphatase-inhibitor-containing buffer, quantify protein, separate proteins by SDS-PAGE, transfer proteins to membrane, probe with phospho-site-specific antibody, strip or run matched blots for total target protein, and normalize phospho-signal to total protein or loading control^[3][7].
• Step 2: For immunoprecipitated kinase activity, lyse samples under non-denaturing conditions, immunoprecipitate the kinase with a specific antibody, wash immune complexes, incubate the kinase with ATP and a validated substrate, then detect phosphorylation by phospho-antibody, ADP generation, or radiolabeled phosphate incorporation^[1][2][7].
• Step 3: For radiometric kinase assay, incubate recombinant or immunoprecipitated kinase with substrate and^[γ-32P]ATP, stop the reaction, separate or capture phosphorylated substrate, and quantify incorporated radioactivity; published protocols emphasize measuring incorporation as a function of time and enzyme concentration^[1].
• Step 4: For ADP-based kinase assay, complete the kinase reaction, remove or deplete remaining ATP, convert ADP to ATP, and measure luciferase-generated luminescence proportional to ADP production; this format is suitable for kinase inhibitor screening when assay linearity and interference are validated^[2][13].
• Step 5: For phospho-immunofluorescence, fix treated cells, organoids, neurons, macrophages, or tissue sections, permeabilize when intracellular epitopes are targeted, stain with validated phospho-specific antibodies, counterstain nuclei or cell markers when needed, and quantify subcellular phospho-signal by microscopy^[3][5].
• Step 6: For phospho-flow cytometry, fix cells rapidly after stimulation or inhibitor treatment, permeabilize using conditions compatible with the phospho-epitope, stain with phospho-specific antibodies, and acquire single-cell phosphorylation signals with compensation and gating controls^[4][14].
• Step 7: For pathway linkage to ferroptosis or mitophagy, combine kinase/phosphorylation measurements with C11-BODIPY lipid-peroxidation detection or mito-QC reporter imaging only when the study hypothesis connects kinase activity to ferroptosis or mitophagy biology^[8][9][15].

Data Acquisition and Analysis

• For kinase activity assays, report raw signal, background-subtracted signal, enzyme linearity, substrate dependence, ATP dependence, inhibitor concentration-response when relevant, and replicate structure; calculate activity from radiolabeled phosphate incorporation, ADP-derived luminescence, or phospho-substrate intensity according to the detection format^[1][2][13].
• For phosphorylation-state assays, quantify phospho-signal and normalize to total target protein, cell number, tissue area, or internal control as appropriate; interpret phosphorylation as pathway activation only when the phospho-site has known functional meaning or is paired with a kinase activity assay, inhibitor response, or substrate validation^[3][4][5][7].
• Use independent cell cultures, organoid lines, primary preparations, or animals as biological replicates; use repeated wells, imaging fields, blot exposures, or cytometer events as technical measurements rather than independent biological replicates^{[4][5][13][14]}.

Problem: Phospho-signal is weak or absent

• Possible Cause: Phosphorylation was lost during collection or lysis

•Literature-supported Solution: Collect samples rapidly and include phosphatase inhibitors because phospho-epitopes are labile^[3].

Problem: Kinase assay signal is nonlinear

• Possible Cause: Enzyme, ATP, substrate, or reaction time is outside the initial-rate range

•Literature-supported Solution: Optimize enzyme concentration, ATP/substrate concentration, and reaction time before inhibitor testing^[13].

Problem: Phospho-antibody gives nonspecific bands or staining

• Possible Cause: Antibody specificity is insufficient for the sample or fixation condition

•Literature-supported Solution: Validate with stimulated/inhibited samples, total-protein antibody, and phosphatase-treated or negative-control material when possible^[3][5].

Problem: Co-IP-linked kinase assay loses activity

• Possible Cause: Harsh lysis or wash conditions disrupt kinase complexes or enzyme conformation

•Literature-supported Solution: Use non-denaturing immunoprecipitation-compatible conditions and include input and IgG controls^[7].

Problem: Phospho-flow signal varies across samples

• Possible Cause: Delayed fixation or inconsistent permeabilization alters phospho-epitope preservation

•Literature-supported Solution: Fix samples rapidly and standardize permeabilization conditions for the target phospho-epitope^[4][14].

Problem: Drug-screening hits do not reproduce across assay formats

• Possible Cause: Compound interference, ATP competition, or detection-format artifacts

•Literature-supported Solution: Confirm hits with an orthogonal assay such as phospho-Western blot, radiometric assay, ADP-based assay, or phospho-flow depending on the target^{[1][2][4][13]}.